




# BIOSIMILARS: A Safe & Effective Option for Patients


In the U.S., biosimilar usage and approvals are on the rise; broader access to these safe, effective treatments allow patients to initiate biologic therapy earlier in their treatment programs.<sup>1</sup>



A biosimilar is a biologic medicine that is

**highly similar**  
to a brand biologic medicine.

**30+** Approved



FDA has approved more than 30 biosimilars<sup>2</sup> to treat patients suffering from RA, Crohn's Disease, cancer, psoriasis and other conditions;

**90**

more in development<sup>3</sup>


Nearly **70** Available



In Europe, nearly 70 biosimilars available in at least 10 therapeutic classes<sup>4</sup>



Same safety and efficacy as their biologic counterpart



Same mechanism of action



Rigorous FDA testing and review; Less cost to patients and the health system



Companies that manufacture biosimilars are committed to providing safe, effective products

Biosimilars are  
**safe, effective, more affordable and offer improved patient access.**




**safe**



**effective**



**affordable**



**access**



**FRESENIUS  
KABI**

caring for life

**BIO**SPECIALIZED

Visit us:  
[www.biospecialized.com](http://www.biospecialized.com)

#### References

1. Janjigian YY, et al. Talking to patients about biosimilars. *Future Oncol.* 2018;14(23):2403-2414.
2. Center for Drug Evaluation and Research. Available at: <https://bit.ly/3AgzI2n>. Accessed July 29, 2021.
3. FDA-TRACK: Center for Drug Evaluation & Research - Pre-Approval Safety Review - Biosimilars Dashboard. Available at: <https://bit.ly/3zbmwuw>. Accessed September 14, 2021.
4. Biosimilars Approved in Europe. Available at: <http://bit.ly/2vY8hvt>. Accessed February 2, 2021.